- 147 Downloads
Bicalutamide (Casodex®) is a competitive androgen receptor antagonist that inactivates androgen-regulated prostate cell growth and function, leading to cell apoptosis and inhibition of prostate cancer growth. It is administered orally as a once-daily dose. In the EU and a number of other countries, bicalutamide 150 mg/day is approved in men with locally advanced nonmetastatic prostate cancer as immediate therapy either as an adjuvant to active treatment or as monotherapy as an alternative to surgical or medical castration.
Combined analysis of the three trials that comprise the bicalutamide Early Prostate Cancer (EPC) programme showed that bicalutamide administered in conjunction with standard care in men with locally advanced prostate cancer offers disease-free survival benefits over standard care alone and is generally well tolerated. Overall survival was improved to a greater extent in the subgroup of patients who received bicalutamide plus radiation therapy compared with radiation therapy alone. Men with localised prostate cancer do not benefit from the addition of bicalutamide to standard care. Combined analysis of two other studies in men with locally advanced prostate cancer show that bicalutamide monotherapy offers better tolerability and higher health-related quality-of-life (HR-QOL) scores for sexual interest and physical capacity compared with surgical or medical castration, while achieving disease-free and overall survival durations that were not significantly different. Thus, when treatment options are being evaluated, bicalutamide as adjuvant therapy or monotherapy should be considered as an alternative to other available hormonal therapies in men with locally advanced prostate cancer, especially in those who wish to maintain an active lifestyle.
Bicalutamide, a competitive androgen receptor antagonist, binds to cytosolic androgen receptors in prostate cells and inactivates androgen-regulated prostate cell growth and function. This leads to cell apoptosis and inhibition of prostate cancer growth. Unlike steroidal antiandrogens, bicalutamide has no progestogenic activity and does not suppress gonadotropin secretion or sex hormone production. Rather, it increases serum levels of luteinising hormone, testosterone, dihydrotestosterone, estradiol and follicle-stimulating hormone. Although increased estradiol levels may cause some unwanted hormonal effects, they protect against hot flushes and preserve bone mineral density.
After oral administration, the pharmacologically active (R)-enantiomer of bicalutamide is slowly and extensively absorbed. Mean steady-state plasma concentrations of (R)-bicalutamide are seen after about 4 weeks’ administration of bicalutamide 150 mg/day in men with prostate cancer. (R)-bicalutamide is >99% bound to plasma albumin. Consistent with a long plasma half-life (t½β) of almost 6 days, (R)-bicalutamide accumulates 10-fold after repeated administration. Bicalutamide undergoes extensive hepatic metabolism, and is excreted in approximately equal proportions in urine and faeces. In patients with severe hepatic impairment, the t½β of (R)-bicalutamide is increased 1.75-fold. Although metabolism of (R)-bicalutamide is predominantly mediated via the cytochrome P450 (CYP) 3A4 isoenzyme, there is no evidence of clinically significant drug interactions when bicalutamide ≤150 mg/day is coadministered with drugs that induce or inhibit CYP enzyme activity.
The efficacy of bicalutamide has been evaluated in conjunction with standard care in men with early (localised or locally advanced) prostate cancer in the EPC programme (n = 8113) and as monotherapy in men with locally advanced prostate cancer in two comparative studies. Combined data from the three EPC trials showed that bicalutamide plus standard care (watchful waiting, radical prostatectomy or radiation therapy) was more effective than standard care alone in improving objective progression-free survival in men with locally advanced prostate cancer at a median follow-up of 7.4 years. In addition, overall survival was improved to a greater extent in men with locally advanced prostate cancer who received bicalutamide plus radiation therapy compared with radiation therapy alone. Bicalutamide did not confer a progression-free or overall survival benefit to men with localised prostate cancer in the EPC programme.
Although equivalence could not be established, progression-free and overall survival durations with bicalutamide were not significantly different from those with surgical or medical castration at a median 6.3 years’ follow-up in the combined results of the two monotherapy studies (n = 480). However, at 12 months’ follow-up, HR-QOL scores for sexual interest and physical capacity were higher in bicalutamide recipients than in men who had been castrated.
The most frequently occurring adverse events associated with bicalutamide as adjuvant therapy or monotherapy were gynaecomastia and breast pain, although these adverse events were generally mild to moderate in severity. Adverse events, such as hot flushes (9.2% vs 5.4%), decreased libido (3.6% vs 1.2%), impotence (9.3% vs 6.5%) and abnormal liver function tests (3.1% vs 1.7%), and death from heart failure (1.2% vs 0.6%) were infrequent in both the bicalutamide and placebo arms in the EPC programme. In the monotherapy trials, the incidence of hot flushes in men who had been castrated was 50% compared with 13% in bicalutamide recipients. After 96 weeks’ treatment in another trial, mean bone mineral density was maintained with bicalutamide, but had decreased in castrated patients.
KeywordsProstate Cancer Bone Mineral Density Androgen Receptor Radical Prostatectomy Advanced Prostate Cancer
- 2.American Cancer Society. Cancer facts and figures 2006. Atlanta (GA): American Cancer Society, 2006Google Scholar
- 5.Aus G, Abbou CC, Bolla M, et al. European Association of Urology guidelines on prostate cancer [online]. Available from URL: http://www.uroweb.org/ [Accessed 2006 Feb 20]
- 10.National Comprehensive Cancer Network. Clinical practice guidelines in oncology v.2.2005: prostate cancer [online]. Available from URL: http://www.nccn.org [Accessed 2006 Feb 20]
- 24.AstraZeneca. Casodex 150mg international prescribing information [online]. Available from URL: http://www.casodex.net [Accessed 2005 Nov 21]
- 25.AstraZeneca UK Limited. Casodex 150 mg film-coated tablets. SPC from the eMC [online]. Available from URL: http://www.http://emc.medicines.org.uk [Accessed 2006 Feb 8]
- 28.Wirth MP, See WA, McLeod DG, et al. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the Early Prostate Cancer program at median followup of 5.4 years. J Urol 2004; 172 (5 Pt 1): 1865–70PubMedCrossRefGoogle Scholar
- 30.Iversen P, Tyrrell CJ, Kaisary AV, et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998 Mar; 51: 389–96PubMedCrossRefGoogle Scholar
- 33.Iversen P, Johansson J-E, Lodding P, et al. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. J Urol 2004 Nov; 172 (5 Pt 1): 1871–6PubMedCrossRefGoogle Scholar
- 34.See WA, Iversen P, McLeod DG, et al. Bicalutamide 150 mg in addition to standard care significantly improves prostate specific antigen progression-free survival in patients with early, non-metastatic prostate cancer: median 5.4 years’ follow-up [abstract no. 1062]. J Urol 2004; 171(4) Suppl.: 280. Plus poster presented at the 99th Annual Meeting of the American Urological Association; 2004 May 8–13; San Francisco (CA)Google Scholar
- 35.Iversen P, Johansson J-E, Lodding P, et al. Efficacy and tolerability of bicalutamide in early non-metastatic prostate cancer: latest findings from the Scandinavian Prostatic Cancer Group Study no 6 (SPCG-6) of the Early Prostate Cancer Programme [abstract plus oral presentation]. 21st Annual Congress of the European Association of Urology; 2006 Apr 5–8; ParisGoogle Scholar
- 36.Wirth M, Tyrrell C, Delaere K, et al. Adjuvant therapy with bicalutamide 150mg versus standard care alone: third analysis results from trial 24 of the Early Prostate Cancer Programme. 21st Annual Congress of the European Association of Urology; 2006 Apr 5–8; ParisGoogle Scholar
- 42.Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02 [published erratum appears in J Clin Oncol 2004; 22 (2): 386]. J Clin Oncol 2003 Nov 1; 21(21): 3972–8PubMedCrossRefGoogle Scholar
- 46.Committee on Safety of Medicines. Casodex 150mg (bicalutamide): no longer indicated for treatment of localised prostate cancer [online]. Available from URL: http://www.mhra.gov.uk [Accessed 2006 Apr 6]
- 47.Health Canada. Important drug safety information. [online]. Available from URL: http://www.hc-sc.gc.ca [Accessed 2006 Apr 6]
- 49.Sternberg CN. Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer (EPC) trial programme. BJU Int 2006 Mar; 97(3): 435–8Google Scholar
- 55.Fradet Y, Egerdie B, Anderson M, et al. Assessment of the optimum dose of tamoxifen for the prophylaxis of bicalutamide-associated breast events [abstract no. 186]. Can J Urol 2005; 12(3): 2665Google Scholar
- 56.Boccardo F, Rubagotti A, Conti G, et al. Exploratory study of drug plasma levels during bicalutamide 150 mg therapy coadministered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer. Cancer Chemother Pharmacol 2005; 56: 415–20PubMedCrossRefGoogle Scholar